Valneva Reveals Promising Lyme Vaccine Data, Pfizer Eyes 2026 Approval

Valneva SE announced positive results from its Phase 2 study of the Lyme disease vaccine candidate, VLA15, on March 13, 2024. The data revealed a strong immune response and a favorable safety profile six months after the third booster dose, confirming the vaccine’s potential for annual administration prior to Lyme season.

Lyme disease, a bacterial infection spread by infected ticks, presents symptoms such as a “bull’s-eye” rash, fever, and fatigue. According to the Centers for Disease Control and Prevention (CDC), approximately 476,000 individuals in the United States are diagnosed with Lyme disease each year, with 132,000 cases reported annually in Europe.

The study, identified as VLA15-221, confirmed that the vaccine produced a robust anamnestic immune response across all age groups. Specifically, antibody levels showed significant persistence at month 48, six months after vaccination. The results indicated that an additional dose effectively increased antibody levels, which then gradually decreased but remained well above baseline levels across all study cohorts.

Insights from the Phase 2 Study

Valneva’s findings showed that the three-dose primary vaccination schedule outperformed the two-dose schedule in maintaining higher antibody levels. Geometric mean fold rises (GMFRs) compared to baseline ranged from 9.5-fold for Serotype 1 (ST1) to 15.6-fold for Serotype 2 (ST2) in the three-dose Month 0-2-6 vaccination schedule. Notably, the 5 to 11-year-old age group exhibited the highest GMFR levels, reaching up to 28.5-fold for ST2.

These results substantiate the efficacy of the three-dose vaccination approach and support the inclusion of a yearly booster dose in the upcoming Phase 3 protocols. The safety profile observed six months post-booster was consistent with previous studies, indicating no new safety concerns.

Pfizer Inc. and Valneva entered a collaboration agreement in April 2020, allowing Pfizer to develop and commercialize VLA15. With positive Phase 3 data, Pfizer plans to submit a Biologics License Application to the U.S. Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency by 2026.

Strategic Restructuring and Market Response

In related news, Valneva announced a strategic initiative to optimize its operations, consolidating its French activities in Lyon while closing its Nantes site. This move is designed to enhance operational effectiveness and position the company for long-term success.

As of the latest market data from Benzinga Pro, Valneva shares rose by 7.65%, reaching $9.19 at the time of publication. This positive momentum reflects investor confidence in the company’s promising vaccine candidate and strategic direction.

Valneva’s advancements in Lyme disease vaccine development could play a crucial role in addressing the growing public health concern associated with this condition.